CNS Pharmaceuticals, Inc. announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer, effective March 2, 2026. Dr. Kelley, age 63, most recently served as Chief Medical Officer of Tissium, Inc., from September 2024 to February 2026. From May 2022 to February 2026, Dr. Kelley served as Founder and Chief Executive Officer and Chief Medical Officer of Xenthera, Inc., and continues to serve as an advisor for the assets.
From February 2019 to February 2026, Dr. Kelley provided executive-level medical, clinical, and regulatory leadership services through Wedgemere Consulting, serving as an interim Chief Medical Officer and clinical development lead to biotechnology companies, venture capital-backed startups, pharmaceutical companies, and medical device companies. From July 2020 to October 2021, Dr. Kelley served as Chief Medical Officer of Servier Pharmaceuticals. From April 2019 to April 2020, she served as Chief Medical Officer of X4 Pharmaceuticals, Inc. From January 2016 to May 2018, Dr. Kelley served as Chief Medical Officer of Senseonics Holdings, Inc. From 2011 to 2016, she served as Worldwide Vice President, Medical Affairs at Becton, Dickinson and Company.
Dr. Kelley currently serves on the Dartmouth Medical School Dean?s Advisory Council and on the Board of Directors of the Dartmouth Center for Health Equity. Dr. Kelley received her M.D. from Dartmouth Medical School and her B.A. in Biology from Boston University. On February 27, 2026, the Company and Dr. Sandra Silberman, the Company?s former Chief Medical Officer, entered into a Separation and Severance Agreement (the ?Separation Agreement?), which memorializes the terms of Dr. Silberman?s separation from service with the Company, effective March 2, 2026.
